Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

INTRODUCTION: Abemaciclib is an oral, selective small-molecule CDK 4 and 6 inhibitor. In preclinical models, abemaciclib synergized with programmed cell death protein-1 blockade to enhance antitumor efficacy. Here, we report the safety and anticancer activity of abemaciclib plus pembrolizumab in two...

Descripción completa

Detalles Bibliográficos
Autores principales: Pujol, Jean-Louis, Vansteenkiste, Johan, Paz-Ares Rodríguez, Luis, Gregorc, Vanesa, Mazieres, Julien, Awad, Mark, Jänne, Pasi A., Chisamore, Michael, Hossain, Anwar M., Chen, Yanyun, Beck, J. Thaddeus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551846/
https://www.ncbi.nlm.nih.gov/pubmed/34746886
http://dx.doi.org/10.1016/j.jtocrr.2021.100234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551846/
https://www.ncbi.nlm.nih.gov/pubmed/34746886
http://dx.doi.org/10.1016/j.jtocrr.2021.100234

Ejemplares similares